Ann: NovoSorb MTX First Sales and March 2023 $6m Revenue, page-136

Just look at the SP performance, Mr Market has made a loud and clear what it thought of the Q3 result. To agree otherwise just means you have your head in the sand.
I am not a pessimist nor am I a shorter but a realist and I hold lots of PNV shares. I do believe in the product but just not happy with how it has performed.
Every incremental 1m/mth extra should be achieved relatively easily going forward. To hit 7m/mth in revenue only requires an extra 10% from 6.4m achieved in March 23. Thu, unlike kicks I see them falling at very regular intervals for this financial year.
DW’s words, target is for each sales to achieve min 1m/year, we have 66 in US, 4+ ANZ, 3+ UK/Ireland ( top sale in US getting 3m/year) so shouldn’t be hard.
Posting my own hypothesis for the lumpy performance in Q3, some cannibalisation between MTX and BTM occurred in the period, early adopters (doctors already using and familiar with BTM) opted to also trial the free seeding MTX products in some procedures, thus leading to a drop in usage of BTM ( causing lumpy sales). Q4 will be key in my humble opinion, need to really hit one out of the park.
I have 7 m/mth hit by June 23 and at least 9m/mth achieved by Dec23. As I stated earlier I had 6m/mth hit by Jan23, 2 mths early, hoping for LTH that the reverse happens and 9 m is hit a few mth earlier.
To be a grow stock means we need to grow a regular intervals and not just be happy with hitting a minor monthly milestone.
I do not mind 6-12 mth cost of sales staff while getting their feet wet but I would really like to see our seasoned sales staff (2+years of service) having a minimum of 2m/year in sales as a target.